TIDMORPH

RNS Number : 1819L

Open Orphan PLC

09 September 2021

9 September 2021

Open Orphan plc

("Open Orphan" or the "Company")

Notice of Interim Results

Analyst briefing and investor presentation

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that its interim results for the six-month period ended 30 June 2021 will be released on Monday, 20 September 2021.

Analyst Briefing

A briefing open to analysts will take place remotely via video conference call on Monday 20 September at 9.30am (BST). If you would like the details of this call, please contact Walbrook PR on openorphan@walbrookpr.com.

Investor Presentation

Cathal Friel, Executive Chairman, and Leo Toole, Chief Financial Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on Monday, 20 September 2021 at 6.00pm (BST).

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Open Orphan plc via:

https://www.investormeetcompany.com/open-orphan-plc/register-investor

Investors who already follow Open Orphan plc on the Investor Meet Company platform will automatically be invited.

For further information please contact:

 
 Open Orphan plc                                                           +353 (0) 1 644 0007 
 Cathal Friel, Executive Chairman 
 
 Arden Partners plc (Nominated Adviser and 
  Joint Broker)                                                           +44 (0) 20 7614 5900 
 John Llewellyn-Lloyd / Louisa Waddell / 
  Oscair McGrath 
 
 finnCap plc (Joint Broker)                                               +44 (0) 20 7220 0500 
 Geoff Nash / James Thompson/ Richard Chambers 
 
 Davy (Euronext Growth Adviser and Joint 
  Broker)                                                                  +353 (0) 1 679 6363 
 Anthony Farrell 
 
 Walbrook PR (Financial PR &                  +44 (0)20 7933 8780 or openorphan@walbrookpr.com 
  IR) 
 Paul McManus/ Sam Allen/ Louis Ashe-Jepson                      +44 (0)7980 541 893 / +44 (0) 
                                                            7502 558 258 / +44 (0) 7747 515393 
 
 

Notes to Editors

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing pharmaceutical service/contract research company that is a world leader in testing vaccines and antivirals using human challenge clinical trials. The company provides services to Big Pharma, biotech and government/public health organisations.

Open Orphan runs challenge studies in London from both its 19-bedroom Whitechapel quarantine clinic, opened in February 2021, and its 24-bedroom QMB clinic with its highly specialised on-site virology and immunology laboratory. Open Orphan has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing a number of other models including the world's first COVID-19 human challenge study model as part of the Human Challenge Programme .

Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company's Disease in Motion(R) platform, this unique dataset includes clinical, immunological, virological and digital (wearable) biomarkers. The Disease in Motion platform has many potential applications across a wide variety of end users including big technology, wearables, pharma and biotech companies. Following COVID-19 there is now a renewed interest and investment in infectious diseases.

Open Orphan's Paris office has been providing biometry, data management and statistics to its many European pharmaceutical clients for over 20 years. For over 15 years, the Company's Netherlands office has been providing drug development consultancy and services, including CMC (chemistry, manufacturing and controls), PK and medical writing, to a broad range of European clients. Both offices are now also fully integrated with the London office and working on challenge study contracts as well as supporting third party trial contracts .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORDKFBPABKDFCK

(END) Dow Jones Newswires

September 09, 2021 02:00 ET (06:00 GMT)

Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2024 to Mar 2024 Click Here for more Hvivo Charts.
Hvivo (LSE:HVO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Hvivo Charts.